Carregant...
Suvorexant improves intractable nocturnal enuresis by altering sleep architecture
Little is known about sleep-based approaches to the treatment of nocturnal enuresis (NE). This report is the first to describe the successful use of suvorexant, an orexin receptor antagonist, in a 12-year-old boy with intractable NE. With suvorexant, the frequency of NE gradually decreased from 14 o...
Guardat en:
| Publicat a: | BMJ Case Rep |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Publishing Group
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7970267/ https://ncbi.nlm.nih.gov/pubmed/33727289 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2020-239621 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|